Literature DB >> 6217002

Circulating immune complexes in primary biliary cirrhosis: interactions with lymphoid cells.

J L Dienstag, A M Savarese, R B Cohen, A K Bhan.   

Abstract

To evaluate the interactions between circulating immune complexes (CIC) and lymphoid cells in primary biliary cirrhosis (PBC), we determined (1) whether antibodies to lymphocytes in PBC serum, independent of CIC, could account for binding in the Raji cell assay for CIC and (2) whether CIC or other humoral factors in PBC serum could interact with lymphoid cells to alter their function. We found that three quarters of CIC positive PBC sera bound specifically to Raji cells via complement receptors, while only one quarter had antibodies to lymphoid cells or Raji cells devoid of complement receptors. We also demonstrated factors which inhibited cell-mediated cytotoxicity and suppressor cell activity in PBC sera; however, we found no correlation between the level and presence of CIC or of lymphocyte antibodies and the level or presence of these serum inhibitory factors. Thus, although the detection of CIC in PBC is not artifactual, the contribution of CIC and other serum factors to the other immunological aberrations in PBC remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6217002      PMCID: PMC1536855     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Fc-receptors on human T lymphocytes. I. Transition of Tgamma to Tmu cells.

Authors:  W J Pichler; L Lum; S Broder
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

Review 2.  Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens.

Authors:  K E Hellström; I Hellström
Journal:  Adv Immunol       Date:  1974       Impact factor: 3.543

3.  Immune complexes in acute and chronic liver disease.

Authors:  H C Thomas; D De Villiers; B Potter; H Hodgson; S Jain; D P Jewell; S Sherlock
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

4.  Circulating immune complexes and complement activation in primary biliary cirrhosis.

Authors:  J R Wands; J L Dienstag; A K Bhan; E R Feller; K J Isselbacher
Journal:  N Engl J Med       Date:  1978-02-02       Impact factor: 91.245

5.  The Raji cell radioimmune assay for detecting immune complexes in human sera.

Authors:  A N Theofilopoulos; C B Wilson; F J Dixon
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

6.  Direct evidence for loss of human suppressor cells during active autoimmune disease.

Authors:  A J Strelkauskas; R T Callery; J McDowell; Y Borel; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

7.  In vitro cell-mediated cytotoxicity in primary biliary cirrhosis and chronic hepatitis. Dysfunction of spontaneous cell-mediated cytotoxicity in primary biliary cirrhosis.

Authors:  J M Vierling; D L Nelson; W Strober; D M Bundy; E A Jones
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

8.  Isolation and characterization of naturally occurring subclasses of human peripheral blood T cells with regulatory functions.

Authors:  A J Strelkauskas; V Schauf; B S Wilson; L Chess; S F Schlossman
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

9.  Two functionally distinct subpopulations of human T cells that collaborate in the generation of cytotoxic cells responsible for cell-mediated lympholysis.

Authors:  R L Evans; H Lazarus; A C Penta; S F Schlossman
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

10.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

View more
  1 in total

1.  Complement profile in primary biliary cirrhosis.

Authors:  M Schlesinger; C Benbassat; Y Shoenfeld
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.